UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Zentalis Pharmaceuticals, LLC		
(Name of Issuer)		
Common Stock		
(Title of Class of Securities)		
98943L107		
(CUSIP Number)		
May 29, 2020†		
(Date of Event which Requires Filing of this Statement)		
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:		
[x] Rule 13d-1(b)		
[] Rule 13d-1(c)		
[] Rule 13d-1(d)		
[] Nuic 15u-1(u)		
† Voluntary early filing		

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. Beneficial ownership information contained herein is given as of the date listed above.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Per	rsons. FAL MANAGEMENT (HK) LIMITED
3 4	Check the Appropriate I (a) [] (b) [] SEC Use Only Citizenship or Place of O Hong Kong	Box if a Member of a Group (See Instructions) Organization.
	Number of Shares Beneficially Owned by Each Reporting Person With	5 Sole Voting Power 0 shares 6 Shared Voting Power 2,664,409 shares 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 2,664,409 shares
9	Aggregate Amount Ben 2,664,409 shares	eficially Owned by Each Reporting Person
10	Check if the Aggregate	Amount in Row (9) Excludes Certain Shares (See Instructions) []
11	Percent of Class Represe	ented by Amount in Row (9)
12	Type of Reporting Perso	on (See Instructions)

1	Names of Reporting Per	Sons. AL MANAGEMENT LIMITED
2	Check the Appropriate E	Box if a Member of a Group (See Instructions)
	(b) []	
4	SEC Use Only Citizenship or Place of C Cayman Islands	Organization.
	Number of Shares Beneficially Owned by Each Reporting Person With	5 Sole Voting Power 0 shares 6 Shared Voting Power 2,664,409 shares 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 2,664,409 shares
9	Aggregate Amount Bene 2,664,409 shares	eficially Owned by Each Reporting Person
10	Check if the Aggregate	Amount in Row (9) Excludes Certain Shares (See Instructions) []
11	Percent of Class Represe	ented by Amount in Row (9)
12	Type of Reporting Perso	n (See Instructions)

1	Names of Reporting Persons. TYBOURNE KESARI LIMITED		
3 4	Check the Appropriate I (a) [] (b) [] SEC Use Only Citizenship or Place of C Cayman Islands	Box if a Member of a Group (See Instructions) Organization.	
	Number of Shares Beneficially Owned by Each Reporting Person With	5 Sole Voting Power 0 shares 6 Shared Voting Power 2,664,409 shares 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 2,664,409 shares	
9	Aggregate Amount Bene 2,664,409 shares	eficially Owned by Each Reporting Person	
10	Check if the Aggregate	Amount in Row (9) Excludes Certain Shares (See Instructions) []	
11	Percent of Class Represe	ented by Amount in Row (9)	
12	Type of Reporting Perso	on (See Instructions)	

1	Names of Reporting Persons. VISWANATHAN KRISHNAN		
2	Check the Appropriate I (a) [] (b) []	Box if a Member of a Group (See Instructions)	
3	SEC Use Only		
4	Citizenship or Place of O	Organization.	
	Number of Shares Beneficially Owned by Each Reporting Person With	5 Sole Voting Power 0 shares 6 Shared Voting Power 2,664,409 shares 7 Sole Dispositive Power 0 shares 8 Shared Dispositive Power 2,664,409 shares	
9	Aggregate Amount Ben 2,664,409 shares	eficially Owned by Each Reporting Person	
10	Check if the Aggregate	Amount in Row (9) Excludes Certain Shares (See Instructions) []	
11		ented by Amount in Row (9)	
12	Type of Reporting Perso	on (See Instructions)	

(a) Name of Issu

Zentalis Pharmaceuticals, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices

530 Seventh Avenue, Suite 2201, New York, New York

Item 2

(a) Name of Person Filing

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i) Tybourne Capital Management (HK) Limited ("Tybourne HK");
- ii) Tybourne Capital Management Limited ("Tybourne Cayman");
- iii) Tybourne Kesari Limited ("Tybourne Kesari"); and
- iv) Viswanathan Krishnan ("Mr. Krishnan")

This statement relates to securities held for the accounts of private investment funds for which Tybourne HK serves as the investment advisor. Tybourne Cayman serves as the manager to Tybourne Master Fund and the parent of Tybourne HK. Tybourne Kesari is the parent of Tybourne Cayman. Mr. Krishnan is the principal and sole shareholder of Tybourne Kesari. In such capacities, Tybourne HK, Tybourne Cayman, Tybourne Kesari and Mr. Krishnan may be deemed to have voting and dispositive power over securities held for the private investment funds. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.

(b) Address of Principal Business Office or, if none, Residence

The address of the principal business office of each Tybourne HK and Mr. Krishnan is 30/F, AIA Central, 1 Connaught Road Central, Hong Kong, K3. The address of the registered office of each Tybourne Cayman and Tybourne Kesari is 190 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands.

(c) Citizenship

- i) Tybourne HK is a company incorporated in Hong Kong with limited liability;
- ii) Tybourne Cayman is a company incorporated in the Cayman Islands with limited liability;
- iii) Tybourne Kesari is organized in the Cayman Islands; and
- iv) Mr. Krishnan is a citizen of the United Kingdom.

(d) Title of Class of Securities

Common Stock ("the Shares")

(e) CUSIP Number

98943L107

Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	[]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
(b)	[]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	[]	Insurance Company as defined in Section 3(a)(19) of the Act;
(d)	[]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8)
(e)	[]	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

	(f)	[]	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);		
	(g)	[X]	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);		
	(h)	[]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		
	(i)	[]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);		
	(j)	[X]	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);		
	(k)	[]	Group, in accordance with §240.13d-1(b)(1)(ii)(K).		
Item 4	Ow	nership			
Item 4(a)	Am	Amount Beneficially Owned			
			Reporting Persons may be deemed the beneficial owner of 2,664,409 Shares. All Shares are held for the account of private funds for which Tybourne HK serves as the investment advisor.		
Item 4(b)	Per	Percent of Class			
	calc	ulation	Reporting Persons may be deemed the beneficial owner of approximately 7.4% of the Shares outstanding. The percentage is based on a statement in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the nd Exchange Commission on May 15, 2020, that there were 35,878,518 Shares outstanding as of May 14, 2020.		
Item 4(c)	Nur	nber of	shares as to which each such person has voting and dispositive power:		
(i)	sole	sole power to vote or to direct the vote			
	0 Sł	0 Shares			
(ii)	sha	shared power to vote or to direct the vote			
	2,66	64,409 S	Shares		
(iii)		sole power to dispose or to direct the disposition of			
	0 Sł	nares			
(iv)		_	ver to dispose or to direct the disposition of		
	2,66	54,409 S	Shares		
Item 5	Ow	nership	of Five Percent or Less of a Class		
			ment is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of ive percent of the class of securities, check the following [].		
Item 6	Ow	nership	of More than Five Percent on Behalf of Another Person		
	See	disclosı	ure in Item 2 and 4 hereof.		
Item 7		ntificati npany	ion and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding		
	See	disclosı	ure in Item 2 hereof.		
Item 8	Ide	ntificati	on and Classification of Members of the Group		
	This	s Item 8	is not applicable.		
Item 9	Not	ice of D	dissolution of Group		

This Item 9 is not applicable.

Item 10 Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits Exhibit

99.1 Joint Filing Agreement, executed by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: 29 May 2020

TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED

By: /s/ Catherine Cheung

Catherine Cheung, Chief Operating Officer

TYBOURNE CAPITAL MANAGEMENT LIMITED

By: Tybourne Kesari Limited,

its Parent

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Principal

TYBOURNE KESARI LIMITED

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Principal

VISWANATHAN KRISHNAN

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Individually

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of 29 May 2020, is by and among Tybourne Capital Management (HK) Limited, Tybourne Capital Management Limited, Tybourne Kesari Limited and Viswanathan Krishnan (collectively, the "Filers").

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of Zentalis Pharmaceuticals, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED

By: /s/ Catherine Cheung

Catherine Cheung, Chief Operating Officer

TYBOURNE CAPITAL MANAGEMENT LIMITED

By: Tybourne Kesari Limited,

its Parent

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Principal

TYBOURNE KESARI LIMITED

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Principal

VISWANATHAN KRISHNAN

By: /s/ Viswanathan Krishnan

Viswanathan Krishnan, Individually